Pregledni rad
https://doi.org/10.20471/acc.2022.61.s3.6
Senhance Robotic Radical Prostatectomy; a Review of Literature
Tomislav Kuliš
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Tvrtko Hudolin
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Luka Penezić
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia
Toni Zekulić
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia
Hrvoje Saić
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia
Tomislav Sambolić
; Department of Anesthesiology, Reanimation and Intensive care, University Hospital Center Zagreb, Zagreb, Croatia
Iva Bačak Kocman
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Anesthesiology, Reanimation and Intensive care, University Hospital Center Zagreb, Zagreb, Croatia
Eleonora Goluža
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Anesthesiology, Reanimation and Intensive care, University Hospital Center Zagreb, Zagreb, Croatia
Nikola Knežević
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Željko Kaštelan
; Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Sažetak
Since its introduction 20 years ago, robotic radical prostatectomy has become a
standard of care in the treatment of localized prostate cancer in many Centers. Until recently, they
have all been performed by the only available robotic platform. Senhance is a novel robotic platform
that was approved for clinical use. The term Senhance was used to systematically search PubMed and
Scopus databases for relevant articles that were afterward filtered for appropriate designs and data reports.
There were two reports that met all of the criteria and were included in the review. Both studies
were designed as prospective case series with a total of 234 patients where the data including operative
data and oncological outcomes were reported. The average operative time ranged between 180 and 195
min, with estimated blood loss between 250 and 300 mL. There was 3 Clavien - Dindo grade III, and
1 Clavien - DIndo grade IV complication reported. One of the studies compared it with laparoscopy,
but no significant difference in operative time and blood loss was found. Both studies concluded that
the Senhance is a feasible and safe robotic platform for radical prostatectomy.
Ključne riječi
Senhance; Robotic Prostatectomy: Prostate Cancer
Hrčak ID:
286366
URI
Datum izdavanja:
1.10.2022.
Posjeta: 891 *